3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Prostate Cancer Non-Metastatic
1
Metastatic Hormone-sensitive Prostate Cancer
1
Interventions
pembrolizumab
37
Carboplatin
31
Cisplatin
30
Paclitaxel
23
Nivolumab
21
Pemetrexed
21
Dexamethasone
18
Gemcitabine
18
Ipilimumab
15
Docetaxel
13
Fluorouracil
13
Capecitabine
12
Rituximab
12
Cyclophosphamide
10
Cytarabine
10
Trastuzumab
9
atezolizumab
9
daratumumab
9
olaparib
9
130-nm albumin-bound paclitaxel
8
Lenalidomide
8
Prednisone
8
durvalumab
8
trastuzumab deruxtecan
8
Bevacizumab
7
Bortezomib
7
Fulvestrant
7
Oxaliplatin
7
Vinorelbine
7
cabozantinib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Has results
×
Has announcements
×
darolutamide
×
Clear all
NCT02799602
2025-12-04
ARASENS
Bayer
Phase 3
Completed
1,306 enrolled
25 charts
2 FDA
NCT02200614
2022-06-28
ARAMIS
Bayer
Phase 3
Completed
1,509 enrolled
13 charts
1 FDA